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Abstract
Background: Interval cancers are primary breast cancers diagnosed in women after a negative screening test and before the
next screening invitation. Our aim was to evaluate risk factors for interval cancer and their subtypes and to compare the risk
factors identified with those associated with incident screen-detected cancers.
Methods: We analyzed data from 645,764 women participating in the Spanish breast cancer screening program from 2000–
2006 and followed-up until 2009. A total of 5,309 screen-detected and 1,653 interval cancers were diagnosed. Among the
latter, 1,012 could be classified on the basis of findings in screening and diagnostic mammograms, consisting of 489 true
interval cancers (48.2%), 235 false-negatives (23.2%), 172 minimal-signs (17.2%) and 114 occult tumors (11.3%). Information
on the screening protocol and women’s characteristics were obtained from the screening program registry. Cause-specific
Cox regression models were used to estimate the hazard ratios (HR) of risks factors for interval cancer and incident screen-
detected cancer. A multinomial regression model, using screen-detected tumors as a reference group, was used to assess
the effect of breast density and other factors on the occurrence of interval cancer subtypes.
Results: A previous false-positive was the main risk factor for interval cancer (HR= 2.71, 95%CI: 2.28–3.23); this risk was
higher for false-negatives (HR = 8.79, 95%CI: 6.24–12.40) than for true interval cancer (HR= 2.26, 95%CI: 1.59–3.21). A family
history of breast cancer was associated with true intervals (HR= 2.11, 95%CI: 1.60–2.78), previous benign biopsy with a false-
negatives (HR= 1.83, 95%CI: 1.23–2.71). High breast density was mainly associated with occult tumors (RRR = 4.92, 95%CI:
2.58–9.38), followed by true intervals (RRR = 1.67, 95%CI: 1.18–2.36) and false-negatives (RRR = 1.58, 95%CI: 1.00–2.49).
Conclusion: The role of women’s characteristics differs among interval cancer subtypes. This information could be useful to
improve effectiveness of breast cancer screening programmes and to better classify subgroups of women with different
risks of developing cancer.
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Introduction
Evaluation of the impact of population-based breast cancer
screening programmes is complex and can only be achieved in the
long term. Regular screening contributes to reducing mortality
from breast cancer, but also has adverse effects, such as false-
positives, overdiagnosis and interval cancers [1,2]. The European
guidelines for quality assurance in breast cancer screening and
diagnosis recommend the use of early performance indicators that
provide information of the impact of screening [3]. These
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indicators should measure positive and negative effects to achieve
a long-term balance between benefits and harms. One of the most
important surrogate indicators of the effectiveness of breast cancer
screening programmes is the interval cancer rate.
Interval cancers are primary breast cancers diagnosed in women
after a negative screening test and before the next screening
invitation [3]. Because they are diagnosed by symptoms, affected
women lose the benefit of early detection and, in case of false-
negative results, suffer delayed diagnosis and treatment.
Numerous studies have examined interval cancer rates in
distinct screening programmes [4–13], allowing comparison of the
sensitivity of these programmes. However, most studies do not
distinguish among interval cancer subtypes, which can only be
achieved after a radiological review of both screening and
diagnostic mammograms. Half of interval cancers are true interval
cancers in our context [14], which are tumours that are
undetectable in the last screening participation but become
symptomatic before the next participation. Failure to detect these
tumours is caused by the limitations of the screening test and is
inherent to organized screening process. Retrospectively, false-
negative cancers (i.e., missed) can be seen in the screening
mammogram and their occurrence is associated with the
organization of screening programmes [14–16]. The remaining
subtypes are minimal-sign cancers (which show detectable but
non-specific sign at latest screen) and occult tumours at
mammography (no signs of mammographic abnormalities either
at screening or at diagnostic), which have been less studied since
they account for less than 25% of interval cancers [14].
Study of interval cancers has focused on detecting differences
with screen-detected cancers according to personal and tumor-
related characteristics [14,16–18]. Compared with screen-detected
cancers, interval cancers show a higher prevalence of features
associated with poor prognosis [14,16]. Breast density has also
been related to interval cancer [17,19], showing a positive
association between higher breast density and interval cancer risk.
However, the specific role of breast density on interval cancer
subtypes taking into consideration personal and organizational
characteristics has not been evaluated.
The aim of our study was to evaluate the factors associated with
a higher probability of interval cancer (overall, true interval, false
negative, minimal signs and occult tumours) and to compare them
with those associated with incident screen-detected cancers. We
also studied the influence of breast density on detection mode and
the occurrence of subtypes.
Methods
Ethics Statement
The study was approved by the Mar Teaching Hospital
Research Ethics Committee. The data was analyzed anonymously
and therefore no additional informed consent was required.
Further information about our data and the methods used can be
requested from the authors.
Settings and study population
Population-based breast cancer screening in Spain is offered
individually to 100% of the target population by the National
Health Service. This programme adheres to the European
Guidelines [3] and its results meet the required standards [20].
Each of the 17 administrative regions in Spain is responsible for
the local application and has several radiology units that carry out
screening. Despite the high degree of consensus, regional
application can vary in the target population definition and in
the mammographic screening protocol used (starting age, single or
double reading, etc) [20].
All women aged 50 years (or 45 years depending on the region)
to 69 years are actively invited to participate by letter every 2 years
[20]. The screening programmes stop inviting women with a
breast cancer diagnosis.
We built a retrospective cohort of 645,764 screened women
from 32 radiology units in five regions of Spain who underwent
mammography between January 1, 2000 and December 31, 2006
and who were followed up until June 30, 2009 for interval cancer
identification. These women underwent a total of 1,508,584
screening mammograms (Figure 1). During the study period,
5,309 cancers were detected in routine screening mammograms,
of which 3,547 were detected in successive participations, and
1,653 emerged as interval cancers. Interval cancers with unknown
diagnostic date (n = 16) were excluded. We included both invasive
and in situ carcinomas.
Screening outcomes
Screening mammography has three possible outcomes: a
negative result, a positive result (abnormal findings requiring
further assessments) or early recall (an intermediate mammogram
is performed out of sequence with the screening interval at 6 or 12
months). Cancers detected at intermediate mammogram were
considered screen-detected cancers [3].
A positive result is considered to be screen-detected tumour if,
after further assessments, there is histopathological confirmation of
cancer. Otherwise, the result is considered a false-positive and
woman is invited at 2 years. Further assessments can include non-
invasive procedures (magnetic resonance imaging, ultrasonogra-
phy, additional mammography) and/or invasive (fine-needle
aspiration cytology, core-needle biopsy and open biopsy).
Interval cancer was defined as ‘‘a primary breast cancer arising
after a negative screening episode and before the next invitation to
screening or within 24 months for women who reached the upper
age limit’’ [3]. We extended the definition until the 30th month,
because we allowed a 6 month margin for women to attend each
round. Interval cancers were identified by merging data from the
registers of screening programmes with population-based cancer
registries [21], the regional Minimum Data Set (based on hospital
discharges with information on the main diagnosis) and hospital-
based cancer registries.
Interval cancer classification and breast density
assessment
Interval cancers were classified by three panels, formed by three
experienced radiologists. The panels performed a semi-informed
independent review of both screening and diagnostic mammo-
grams with independent double reading and arbitration. Of 1,653
interval cancers, 1,012 had available screening and diagnostic
mammograms, and therefore could be classified into the four
interval cancer categories. Briefly, screening mammograms were
first reviewed alone and provisionally classified into positive,
negative, and minimal-signs. Afterwards, the screening and
diagnostic mammograms were reviewed together and interval
cancers were definitively classified into: true interval cancers (the
screening mammogram showed normal or benign results), false-
negatives (an abnormality suspicious for malignancy was retro-
spectively seen on the screening mammogram), minimal-signs
(detectable but non-specific signs were identified on the screening
mammogram) and occult tumours (showing no mammographic
abnormalities at diagnosis despite clinical signs) [3]. More details
of the classification process have been reported in a previous study
[15].
Risk Factors on Interval Cancer Subtypes in Breast Cancer Screening
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The breast density of the cancer-free breast was determined by
one radiologist from each panel, using Boyd’s scale, a semi-
quantitative score of six categories using percentages of density: A:
0%; B: 1–10%; C:10–25%; D:25–50%; E:50–75%; F:75–100%
[22]. For purposes of this study, the first three categories were
combined into the ,25% group [23]. Breast density was assessed
for classified interval cancers (N = 1,012) and from a sample of
screen-detected cancers matched by region and year of the last
screening (N = 1,570).
Study variables
All information was collected from each woman at each
attendance. The variables related to the screening protocol
included the reading method (single or double reading) and
mammography type (screen-film mammography [SFM] or digital
mammography [DM]). The variables related to women’s personal
characteristics were use of hormonal replacement therapy (HRT)
at screening or in the previous 6 months (Yes/No), menopausal
status (pre- or postmenopausal), previous benign biopsy outside
screening (Yes/No), the presence or absence of a first-degree
familial history of breast cancer (Yes/No), mammography date,
number of participations, the existence of a previous false-positive
(Yes/No), and the existence of an early recall (Yes/No).
Statistical analysis
Breast cancer rates per 1,000 women and per 10,000
mammograms were estimated, for interval cancers and for
screen-detected cancers.
The cumulative probability of suffering an interval cancer was
calculated using the Kaplan-Meier estimator with time-dependent
variables according the distinct study variables. We estimated the
hazard ratios (HR) of interval cancer and incident screen-detected
cancer using a multivariate cause-specific Cox model with time-
dependent variables. Radiology units were included as a random
Figure 1. Flow chart of the study populations.
doi:10.1371/journal.pone.0110207.g001
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effect [24]. We built explanatory models including all relevant
covariates according to the literature to evaluate their effect and
statistical significance on the risk of cancer detection and of
interval cancer subtypes.
Given that incidence of breast cancer depends on age, we used
age as time scale in the Kaplan-Meier and Cox regression analyses
[25]. Age at study entry was defined as the age at the first
mammogram in the study period. Age at study exit was the lowest
of: age at breast cancer diagnosis, age at the study closure, or age
at 30 months after the last mammogram. Observations were
censored when the event breast cancer diagnosis did not occur
during the study period.
We conducted a case-control analysis to determine whether the
study variables differed between interval cancers (cases) and
screen-detected cancers (controls), using a multivariate logistic
regression model. For the analysis of variables associated to the
subtypes of interval cancer, we fitted a multinomial regression
model, using the screen-detected cancers as a reference group.
The multinomial model estimates k-1 models, comparing each
group to the referent group. The exponentiated multinomial logit
coefficient provides an estimate of the relative risk and, commonly,
is expressed as relative risk ratio (RRR).
All P-values were based on two-sided tests and were considered
statistically significant if less than 0.05. Statistical analyses were
performed using the R statistical software (version 3.0.1) [26].
Results
Interval cancer subtypes and risk factors
The interval cancer rate was 2.57 per 1,000 screened women
and 10.99 per 10,000 screening mammograms (Table 1). The
largest proportion of interval cancers was diagnosed in the second
year (60.0% of interval cancers). The radiologist teams classified
1,012 interval cancers as follows: 489 true intervals, 235 false-
negatives, 174 minimal-signs and 114 occult tumours.
Among classified interval cancers, 42.1% of occult tumours,
32.3% of false-negatives and 31.0% of minimal-signs were
diagnosed in the first 12 months after the participation and only
19.6% of true interval cancers emerged in the same period.
Figure 2 presents the cumulative probability of developing an
interval cancer according to family history of breast cancer,
previous benign biopsy outside screening and the presence of a
previous false-positive result. The other covariates did not show
statistically significant differences in the bivariate analysis (data not
shown). Women with a false-positive result in the previous
participation had a higher cumulative probability of developing
interval cancer than women without (0.033 vs 0.013). Women with
family history of breast cancer or previous benign biopsy result
outside screening had a higher cumulative probability than women
without (0.021 vs 0.012 and 0.022 vs 0.012, respectively).
The hazard risks from cause-specific survival analyses for
incident screen-detected cancers and interval cancers (overall and
subtypes) are shown in Table 2 (see also tables S1 and S2). The
existence of a false-positive in the previous mammogram showed
the highest hazard ratio for developing interval cancer (HR = 2.71;
95% CI: 2.28–3.23), while having an early recall showed the
highest hazard ratio for screen-detected cancer (HR = 3.59; 95%
CI:3.12–4.14). A previous false-positive result, premenopausal
status, a family history of breast cancer and previous benign breast
biopsy were risk factors for both interval and screen-detected
cancers. HRT use was significantly associated with increased risk
of developing interval cancer (HR = 1.27; 95% CI:1.07–1.5). DM
was associated with screen-detected cancer (HR = 1.34; 95% T
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CI:1.12–1.61). Early recall was a protective factor for interval
cancer (HR = 0.56; 95% CI:0.40–0.78).
The effect of the risk factors on developing interval cancer
differed according to subtypes. DM was associated with true
interval cancer (HR = 2.17; 95% CI:1.37–3.45), but not with false-
negatives (HR = 1.57; 95% CI:0.78–3.13). The effect of a previous
false-positive result was higher for false-negatives (HR = 8.79; 95%
CI:6.24–12.40) than for true interval cancer (HR = 2.26; 95%
CI:1.59–3.21). HRT use was a statistically significant risk factor for
minimal-signs (HR = 1.63; 95% CI:1.03–2.56) and a family history
of breast cancer was a risk factor for true interval cancer
(HR = 2.11; 95% CI:1.60–2.78) and minimal-signs as well
(HR = 1.67; 95% CI:1.02–2.74). Previous benign biopsy outside
screening was a risk factor for a false-negative cancers (HR = 1.83;
95% CI:1.23–2.71).
Comparison of breast density and other risk factors
between interval cancers and screen detected cancers
The proportion of women with extremely dense breasts
(Table 3) was higher for interval cancers than for screen-detected
cancers (16.4% and 11.7%, respectively, P,0.001); the highest
proportion was found in occult tumours (28.1%) and the lowest in
minimal-signs cancers (9.8%).
Table 4 presents the risk factors associated with interval cancers
compared with screen-detected cancers. Risk factors for overall
interval cancer were the presence of a previous false-positive
(OR = 2.11; 95% CI:1.56–2.86), HRT use (OR = 1.57; 95%
CI:1.18–2.10) and extremely dense breasts (OR = 1.63; 95%
CI:1.24–2.14). By interval cancer subtypes, risk factors for true
interval cancer were the same as those for interval cancer: the
presence of a previous false-positive (RRR = 1.79; 95% CI:1.21–
2.63), HRT use (RRR = 1.57; 95% CI:1.10–2.25) and extremely
dense breasts (RRR = 1.67; 95% CI:1.18–2.36). However, for false
negatives, only the presence of a previous false-positive result was a
risk factor (RRR = 4.55; 95% CI:3.07–6.75), which was the
strongest observed association in this analysis. Extremely breast
density was at the limit of significance (RRR = 1.58; 95% CI:1.00–
2.49). The only statistically significant risk factor for minimal signs
was HRT use (RRR = 1.84; 95% CI:1.12–3.02), and that for
occult tumours was extremely breast density (RRR = 4.92; 95%
CI:2.58–9.38).
Discussion
This study provides information on the determinants of interval
cancer and its subtypes and a comparison with screen-detected
cancer in a retrospective cohort of screened women. Women’s
characteristics (premenopausal status, a family history of breast
cancer, and previous benign breast biopsy) were risk factors for
both interval and screen-detected cancer, showing a similar
strength of association. A family history of breast cancer had the
strongest association with true interval cancer while previous
benign biopsy was a significant risk factor only for false-negatives.
The presence of a previous false-positive result was a risk factor for
both screen-detected and interval cancer but the association with
interval cancer was stronger, especially for false-negative cancers.
Double reading, digital mammography and early recall were
associated with screen-detected cancer but not with interval
cancer.
Few studies have analysed the determinants of interval cancer
and even fewer have taken subtypes into account. Previous studies
have described interval cancer rates ranging from 1.8 to 2.9 per
1,000 women and from 10.6 to 29.5 per 10,000 mammograms [4–
13], which are consistent with our results. The main risk factor for
interval cancer was a previous false-positive result, with the
strongest association for false-negatives, suggesting that some
results interpreted as false-positives may, in fact, be false-negatives
[27–29]. In fact, false positive have been found also a risk factor for
screen cancer detection especially when cytology or biopsy had
been performed as further assessment [30,31].
DM was not associated with increased risk of interval cancer, in
line with the study by Hoff et al. [32] and a recent study from
Norway [33], showing that DM use did not modify false-negatives
rates. The increased risk of true interval cancers with DM could be
explained by the higher precision in detecting less advanced and
Figure 2. Cumulative hazard for interval cancer by the presence of a previous false-positive result, family history of breast cancer
and previous benign biopsy outside screening.
doi:10.1371/journal.pone.0110207.g002
Risk Factors on Interval Cancer Subtypes in Breast Cancer Screening
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e110207
smaller tumours with DM, which has been demonstrated in
several studies carried out in mammography screening contexts
[32–35].
Premenopausal status, a family history of breast cancer and
previous benign breast biopsy result are well-known risk factors for
breast cancer [36], which is coherent with our findings and those
of previous studies, revealing an association with both incident
screen-detected and interval cancer [9,18,37]. However, the role
of these factors seemed to differ when we specifically analysed
subtypes. HRT use was a risk factor for minimal-signs, but we
have no information on HRT type or on treatment length, which
could have affected these findings [37]. The effect of family history
was greater for true interval cancer, in agreement with the
hypothesis that tumours in women with a family history of breast
cancer grow faster and are more aggressive [16,38].
Because information on breast density was not available for the
whole cohort, we analyzed the effect of breast density as a risk
factor for interval cancer subtypes compared with those of screen-
detected cancers in a case-control. In previous study in the same
cohort we explored the role of breast density within interval cancer
subtypes, adjusting by tumour characteristics [15]. In the current
work, we considered women-related and organizational charac-
teristic, obtaining consistent results. High breast density was a risk
factor for interval cancer, mainly for occult tumours, but also for
true interval and false-negatives. Pollan et al. observed that breast
density played a greater role in interval cancer than in screen-
detected cancer [19]. The strong association of breast density and
occult tumours pointed to a masking effect, but breast density
appears to play a lesser role in false-negatives. The association with
true interval cancer also reinforce the hypothesis that tumours
stimulated by growth factors found in dense breasts [39] are more
likely to be true interval cancers. Understanding the role of breast
density is important in breast cancer screening since it is one of the
variables proposed to tailor screening.
This study has some limitations. First, we could not get all
diagnostic mammograms from interval cancers mainly because
logistic reasons, avoiding a complete interval cancer classification.
Moreover, misclassification among interval cancers cannot be
excluded because is inherent to radiologist subjectivity. However,
this misclassification would attenuate differences among study
groups. Breast density was not available for the entire population
because it was not systematically collected and registered.
Table 2. Adjusted hazard ratios from cause-specific survival analyses for incident screen-detected cancers and for interval cancer
(overall and subtypes).
Incident SDC IC TI FN MS OT
HR* (95%CI) HR* (95%CI) HR* (95%CI) HR* (95%CI) HR* (95%CI) HR* (95%CI)
Reading Method
Double Ref Ref Ref Ref Ref Ref
Single 1.31 (0.85–2.02) 0.85 (0.60–1.21) 1.55 (0.66–3.62) 1.09 (0.36–3.25) 1.38 (0.26–7.28) 0.52 (0.15–1.81)
Type of mammogram
SFM Ref Ref Ref Ref Ref Ref
DM 1.34 (1.12–1.61) 1.00 (0.78–1.28) 2.17 (1.37–3.45) 1.57 (0.78–3.13) 0.97 (0.35–2.67) 0.36 (0.11–1.24)
Early Recall
No Ref Ref Ref Ref Ref +
Yes 3.59 (3.12–4.14) 0.56 (0.40–0.78) 0.46 (0.22–0.96) 0.36 (0.15-0.83) 0.85 (0.29–2.46)
Previous false-positive
No Ref Ref Ref Ref Ref Ref
Yes 1.34 (1.20–1.60) 2.71 (2.28–3.23) 2.26 (1.59–3.21) 8.79 (6.24–12.40) 1.80 (0.93–3.47) 0.34 (0.08–1.39)
HRT use
No Ref Ref Ref Ref Ref Ref
Yes 0.98 (0.86–1.11) 1.27 (1.07–1.50) 1.33 (0.99–1.79) 1.30 (0.82–2.05) 1.63 (1.03–2.56) 0.92 (0.46–1.84)
Menopausal status
Postmenopausal Ref Ref Ref Ref Ref Ref
Premenopausal 1.26 (1.09–1.45) 1.41 (1.20–1.67) 1.29 (0.94–1.76) 1.28 (0.79–2.07) 0.91 (0.52–1.61) 1.33 (0.78–2.27)
Family history of breast cancer
No Ref Ref Ref Ref Ref Ref
Yes 1.75 (1.56–1.94) 1.65 (1.41–1.93) 2.11 (1.60–2.78) 1.44 (0.91–2.27) 1.67 (1.02–2.74) 1.44 (0.77–2.69)
Previous benign biopsy outside
screening
No Ref Ref Ref Ref Ref Ref
Yes 1.34 (1.18–1.53) 1.73 (1.46–2.04) 1.26 (0.90–1.74) 1.83 (1.23–2.71) 1.44 (0.87–2.37) 1.12 (0.54–2.33)
*Multivariate Cox time-dependent models. The hazard ratios for each variable were adjusted for the other variables in the table, the year of the last mammogram, and
for radiology unit (as a random effect).
+We excluded early recall, because there were no cases of early recall in occult tumors.
Abbreviations: SDC: Screen-detected cancer, IC: Interval Cancer, TI: True interval, FN: False-negative, MS: Minimal-signs, OT: Occult tumors, SFM: Screen-film
mammography, DM: Digital mammography and HRT: Hormonal Replacement Therapy.
doi:10.1371/journal.pone.0110207.t002
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Therefore, we could not include this factor in the analysis of
determinants. In addition, breast density was visually assessed,
implying also some subjectivity and misclassification. Equally,
information was unavailable on other important cancer-related
variables such as age at menarche, age at maternity, the number of
children and body mass index, type of mammographic abnormal-
ity and clinico-histopathological features of the breast cancers. The
small numbers of occult tumours did not provide sufficient
statistical power for this subgroup in some analyses.
Table 3. Distribution of variables related to the screening protocol and women’s characteristics by screen-detected and interval
cancer (overall and subtypes).
SDC IC TI FN MS OT
N (%) N (%) N (%) N (%) N (%) N (%)
Total 1,570 1,012 489 235 174 114
Reading method
Double 1,450 (92.4) 889 (87.8)* 424 (86.7) 202 (86.0) 162 (93.1) 101 (88.6)+
Single 120 (7.6) 123 (12.2) 65 (13.3) 33 (14.0) 12 (6.9) 13 (11.4)
Type of Mammogram
SFM 1,470 (93.6) 941 (93.0) 446 (91.2) 216 (91.9) 168 (96.6) 111 (97.4)+
DM 100 (6.4) 71 (7.0) 43 (8.8) 19 (8.1) 6 (3.4) 3 (2.6)
Participation
Successive 1,100 (70.1) 742 (73.3) 361 (73.8) 176 (74.9) 128 (73.6) 77 (67.5)
Initial 470 (29.9) 270 (26.7) 128 (26.2) 59 (25.1) 46 (26.4) 37 (32.5)
Early Recall
No 1,423 (90.6) 985 (97.3)* 474 (96.9) 227 (96.6) 170 (97.7) 114 (100.0)+
Yes 147 (9.4) 27 (2.7) 15 (3.1) 8(3.4) 4 (2.3) 0 (0.0)
Previous false-positive
No 1,475 (93.9) 904 (89.3)* 444 (90.8) 185 (78.7) 163 (93.7) 112 (98.2)+
Yes 95 (6.1) 108 (10.7) 45 (9.2) 50 (21.3) 11 (6.3) 2 (1.8)
Age group (yrs)
44–49 81 (5.2) 61 (6.1)* 32 (6.5) 12 (5.1) 8 (4.6) 10 (8.8)+
50–54 421 (26.8) 351 (34.7) 170 (34.8) 73 (31.1) 54 (31.0) 54 (47.4)
55–59 438 (27.9) 271 (26.8) 136 (27.8) 57 (24.3) 55 (31.6) 23 (20.2)
60–64 460 (29.3) 224 (22.1) 103 (21.1) 62 (26.4) 39 (22.4) 20 (17.5)
65–70 170 (10.8) 104 (10.3) 48 (9.8) 31 (13.2) 18 (10.3) 7 (6.1)
HRT use
No 1,306 (91.5) 771 (87.9)* 366 (87.6) 175 (88.8) 139 (85.8) 91 (91.0)+
Yes 122 (8.5) 106 (12.1) 52 (12.4) 22 (11.2) 23 (14.2) 9 (9.0)
Menopausal status
Postmenopausal 1,222 (85.5) 725 (81.7)* 346 (81.6) 166 (83.0) 138 (86.8) 75 (72.1)+
Premenopausal 207 (14.5) 162 (18.3) 78 (18.4) 34 (17.0) 21 (13.2) 29 (27.9)
Family history of breast cancer
No 1,224 (87.5) 760 (87.5) 352 (85.6) 175 (89.3) 139 (88.5) 94 (89.5)
Yes 175 (12.5) 109 (12.5) 59 (14.4) 21 (10.7) 18 (11.5) 11 (10.5)
Previous benign biopsy outside screening
No 1,168 (88.1) 717 (88.0) 347 (89.4) 158 (83.6) 134 (88.1) 78 (90.7)
Yes 158 (11.9) 98 (12,0) 41 (10.6) 31 (16.4) 18 (11.8) 8 (9.3)
Density
,25% 607 (38.7) 325 (32.1)* 153 (31.3) 86 (36.6) 68 (39.1) 18 (15.8)+
25–50% 428 (27.3) 169 (26.6) 134 (27.4) 64 (27.2) 49 (28.2) 22 (19.3)
50–75% 352 (22.4) 252 (24.9) 123 (25.2) 47 (20.0) 40 (23.0) 42 (36.8)
.75% 183 (11.7) 166 (16.4) 79 (16.2) 38 (16.2) 17 (9.8) 32 (28.1)
*P-value,0.05, Chi-squared test between screen-detected and interval cancer.
+P-value,0.05, Chi-squared test between screen-detected and interval cancer subtype.
Abbreviations: SDC: Screen-detected Cancer, IC: Interval Cancer, TI: True interval, FN: False-negative, MS: Minimal-signs, OT: Occult tumours, SFM: Screen-film
mammography, DM: Digital mammography and HRT: Hormone Replacement Therapy.
doi:10.1371/journal.pone.0110207.t003
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A strength of study was the cohort size and the consolidation of
the screening programmes in Spain. The participating radiology
units had completed at least five rounds ensuring the quality
indicators were stable. There are other studies with radiologically
classified interval cancers, but the present is, to our knowledge, the
largest one with information on breast density for the different
subtypes.
In conclusion, the current work provides comprehensive data on
the relationship between personal and organizational character-
istics and the risk of interval cancer. This information could be
useful to better classify subgroups of women at different risks of
developing cancer in a moment when personalization of breast
cancer screening is being proposed [40]. The strong relationship
observed between false-positives results and false negatives,
together with the previous knowledge on the relationship between
false-positive and cancer, emphasizes the need for return for
further screening in women with false-positive results, and calls for
more research on this topic.
Supporting Information
Table S1 Incidence of variables related to the screening
protocol and women’s characteristics by screen-detect-
ed and interval cancer (overall and subtypes).
(DOC)
Table S2 Crude hazard ratios from cause-specific
survival analyses for incident screen-detected cancers
and for interval cancer (overall and subtypes).
(DOC)
Table 4. Adjusted odds ratio (OR) or relative risk ratios (RRR) for interval cancer and subtypes compared with screen-detected
cancers.
IC TI FN MS OT
OR* (95%CI) RRR** (95%CI) RRR** (95%CI) RRR** (95%CI) RRR** (95%CI)
Reading method
Single vs Double 1.55 (0.84–2.91) 1.60 (0.75–3.42) 1.67 (0.62–4.55) 2.09 (0.45–9.75) 1.03 (0.24–4.47)
Type of Mammogram
DM vs SFM 0.61 (0.40–0.90) 0.84 (0.52–1.37) 0.56 (0.29–1.11) 0.37 (0.14–0.99) 0.21 (0.06–0.79)
Participation
Initial vs Successive 0.70 (0.57–0.87) 0.66 (0.50–0.87) 0.78 (0.53–1.13) 0.77 (0.51–1.16) 0.65 (0.40–1.06)
Early Recall
Yes vs No 0.23 (0.14–0.35) 0.27 (0.15–0.47) 0.25 (0.11–0.55) 0.23 (0.08–0.64) +
Previous false-positive
Yes vs No 2.11 (1.56–2.86) 1.79 (1.21–2.63) 4.55 (3.07–6.75) 1.15 (0.59–2.21) 0.32 (0.08–1.33)
Age group (yrs)
44–49 vs 50–54 1.07 (0.71–1.59) 1.17 (0.71–1.91) 0.87 (0.42–1.79) 1.05 (0.45–2.43) 1.17 (0.53–2.59)
55–59 vs 50–54 0.65 (0.51–0.82) 0.65 (0.48–0.88) 0.69 (0.45–1.06) 0.80 (0.51–1.26) 0.37 (0.21–0.66)
60–64 vs 50–54 0.52 (0.40–0.67) 0.49 (0.35–0.67) 0.71 (0.46–1.10) 0.53 (0.32–0.87) 0.36 (0.19–0.66)
65–70 vs 50–54 0.65 (0.47–0.89) 0.61 (0.41–0.92) 0.92 (0.54–1.55) 0.67 (0.36–1.24) 0.31 (0.13–0.75)
HRT use
Yes vs No 1.57 (1.18–2.10) 1.57 (1.10–2.25) 1.48 (0.89–2.44) 1.84 (1.12–3.02) 1.26 (0.60–2.64)
Menopausal status
Pre vs Postmenopausal 0.91 (0.67–1.22) 0.91 (0.63–1.32) 1.00 (0.60–1.68) 0.77 (0.42–1.40) 0.84 (0.46–1.53)
Family history of breast cancer
Yes vs No 0.98 (0.75–1.28) 1.16 (0.84–1.61) 0.80 (0.49–1.31) 0.91 (0.54–1.53) 0.75 (0.38–1.46)
Previous benign biopsy outside screening
Yes vs No 0.89 (0.67–1.17) 0.77 (0.53–1.12) 1.19 (0.77–1.85) 0.94 (0.55–1.60) 0.70 (0.32–1.49)
Density
25–50% vs ,25% 1.18 (0.95–1.46) 1.26 (0.96–1.66) 1.12 (0.78–1.61) 0.99 (0.66–1.47) 1.53 (0.80–2.94)
50–75% vs ,25% 1.28 (1.03–1.60) 1.33 (1.00–1.77) 0.97 (0.65–1.44) 0.93 (0.61–1.43) 3.54 (1.97–6.36)
.75% vs ,25% 1.63 (1.24–2.14) 1.67 (1.18–2.36) 1.58 (1.00–2.49) 0.74 (0.41–1.34) 4.92 (2.58–9.38)
The last category in each row is the reference category.
*Logistic regression between screen-detected (ref) and interval cancer. The ORs are adjusted for the other variables in the table and the year of last mammogram.
**Multinomial regression between screen-detected (ref) and subtypes of interval cancer. The RRRs are adjusted for the other variables in the table and the year of last
mammogram.
+We excluded early recall, because there were no cases of early recall in occult tumors. All the estimates are also adjusted by mammogram year.
Abbreviations: SDC: Screen-detected cancer, IC: Interval Cancer, TI: True interval, FN: False-negative, MS: Minimal-signs, OT: Occult tumours, SFM: Screen-film
mammography, DM: Digital mammography and HRT: Hormone Replacement Therapy.
doi:10.1371/journal.pone.0110207.t004
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